Cerca una sperimentazione clinica

Altra/e opzione/i di ricerca

11 Risultato/i

11 Sperimentazioni cliniche nazionali

Sperimentazione in fase di reclutamento = ; Sperimentazione in corso = ; Sperimentazione conclusa = ; Finanziato da un ente associato a IRDiRC = ; Studio che coinvolge i membri delle ERN in almeno due Stati =

Sperimentazioni cliniche nazionali

SPAGNA

Cataluña
MATARÓ

ADVANCE: A randomized, double-blind, placebo-controlled, multinational, multicenter study with open-label treatment extension to assess the effect of MIN-102 on the progression of adrenomyeloneuropathy in male patients with X-linked adrenoleukodystrophy -ES
Minoryx Therapeutics S.L.

Ulteriori dettagli

SPAGNA

Cataluña
MATARÓ

ADVANCE: A randomized, double-blind, placebo-controlled, multinational, multicenter study with open-label treatment extension to assess the effect of MIN-102 on the progression of adrenomyeloneuropathy in male patients with X-linked adrenoleukodystrophy - GB
Minoryx Therapeutics S.L.

Ulteriori dettagli

SPAGNA

Cataluña
MATARÓ

ADVANCE: A randomized, double-blind, placebo-controlled, multinational, multicenter study with open-label treatment extension to assess the effect of MIN-102 on the progression of adrenomyeloneuropathy in male patients with X-linked adrenoleukodystrophy (Phase II-III) -DE-
Minoryx Therapeutics S.L.

Ulteriori dettagli

SPAGNA

Cataluña
MATARÓ

FRAMES: A Double-Blind, Placebo-controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological and Clinical Markers in Patients With Friedreich's Ataxia - BE
Minoryx Therapeutics S.L.

Ulteriori dettagli

SPAGNA

Cataluña
MATARÓ

FRAMES: A Double-Blind, Placebo-controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological and Clinical Markers in Patients With Friedreich's Ataxia -DE-
Minoryx Therapeutics S.L.

Ulteriori dettagli

SPAGNA

Cataluña
MATARÓ

NEXUS: An exploratory, open-label, multicenter study in male pediatric patients with cerebral X-linked Adrenoleukodystrophie (cALD) to assess the effect of MIN-102 treatment on the progression of cerebral lesions -ES
Minoryx Therapeutics S.L.

Ulteriori dettagli

SPAGNA

Cataluña
MATARÓ

FRAMES: A Double-Blind, Placebo-controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological and Clinical Markers in Patients With Friedreich's Ataxia - ES (completed)
Minoryx Therapeutics S.L.

Ulteriori dettagli

SPAGNA

Cataluña
MATARÓ

An Open-label, Multicenter Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) -FR
Minoryx Therapeutics S.L.

Ulteriori dettagli

SPAGNA

Cataluña
MATARÓ

NEXUS: An Open-label, Multicenter Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) -DE
Minoryx Therapeutics S.L.

Ulteriori dettagli

SPAGNA

Cataluña
MATARÓ

ADVANCE: A randomized, double-blind, placebo-controlled, multinational, multicenter study with open-label treatment extension to assess the effect of MIN-102 on the progression of adrenomyeloneuropathy in male patients with X-linked adrenoleukodystrophy - FR
Minoryx Therapeutics S.L.

Ulteriori dettagli

SPAGNA

Cataluña
MATARÓ

ADVANCE: Studio per valutare l'effetto di MIN-102 paragonato al placebo dopo 96 settimane di trattamento randomizzato in doppio cieco seguito da uno studio di estensione in aperto per valutare l'effetto a lungo termine del trattamento con MIN-102 sulla progressione della adrenomieloneuropatia (AMN) in pazienti maschi
Minoryx Therapeutics S.L.

Ulteriori dettagli

Cerca una sperimentazione clinica

Altra/e opzione/i di ricerca

11 Risultato/i

Sperimentazioni cliniche nazionali

ADVANCE: A randomized, double-blind, placebo-controlled, multinational, multicenter study with open-label treatment extension to assess the effect of MIN-102 on the progression of adrenomyeloneuropathy in male patients with X-linked adrenoleukodystrophy -ES Minoryx Therapeutics S.L.

ADVANCE: A randomized, double-blind, placebo-controlled, multinational, multicenter study with open-label treatment extension to assess the effect of MIN-102 on the progression of adrenomyeloneuropathy in male patients with X-linked adrenoleukodystrophy - GB Minoryx Therapeutics S.L.

ADVANCE: A randomized, double-blind, placebo-controlled, multinational, multicenter study with open-label treatment extension to assess the effect of MIN-102 on the progression of adrenomyeloneuropathy in male patients with X-linked adrenoleukodystrophy (Phase II-III) -DE- Minoryx Therapeutics S.L.

FRAMES: A Double-Blind, Placebo-controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological and Clinical Markers in Patients With Friedreich's Ataxia - BE Minoryx Therapeutics S.L.

FRAMES: A Double-Blind, Placebo-controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological and Clinical Markers in Patients With Friedreich's Ataxia -DE- Minoryx Therapeutics S.L.

NEXUS: An exploratory, open-label, multicenter study in male pediatric patients with cerebral X-linked Adrenoleukodystrophie (cALD) to assess the effect of MIN-102 treatment on the progression of cerebral lesions -ES Minoryx Therapeutics S.L.

FRAMES: A Double-Blind, Placebo-controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological and Clinical Markers in Patients With Friedreich's Ataxia - ES (completed) Minoryx Therapeutics S.L.

An Open-label, Multicenter Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) -FR Minoryx Therapeutics S.L.

NEXUS: An Open-label, Multicenter Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) -DE Minoryx Therapeutics S.L.

ADVANCE: A randomized, double-blind, placebo-controlled, multinational, multicenter study with open-label treatment extension to assess the effect of MIN-102 on the progression of adrenomyeloneuropathy in male patients with X-linked adrenoleukodystrophy - FR Minoryx Therapeutics S.L.

ADVANCE: A randomized, double-blind, placebo-controlled, multinational, multicenter study with open-label treatment extension to assess the effect of MIN-102 on the progression of adrenomyeloneuropathy in male patients with X-linked adrenoleukodystrophy -ES
Minoryx Therapeutics S.L.

ADVANCE: A randomized, double-blind, placebo-controlled, multinational, multicenter study with open-label treatment extension to assess the effect of MIN-102 on the progression of adrenomyeloneuropathy in male patients with X-linked adrenoleukodystrophy - GB
Minoryx Therapeutics S.L.

ADVANCE: A randomized, double-blind, placebo-controlled, multinational, multicenter study with open-label treatment extension to assess the effect of MIN-102 on the progression of adrenomyeloneuropathy in male patients with X-linked adrenoleukodystrophy (Phase II-III) -DE-
Minoryx Therapeutics S.L.

FRAMES: A Double-Blind, Placebo-controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological and Clinical Markers in Patients With Friedreich's Ataxia - BE
Minoryx Therapeutics S.L.

FRAMES: A Double-Blind, Placebo-controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological and Clinical Markers in Patients With Friedreich's Ataxia -DE-
Minoryx Therapeutics S.L.

NEXUS: An exploratory, open-label, multicenter study in male pediatric patients with cerebral X-linked Adrenoleukodystrophie (cALD) to assess the effect of MIN-102 treatment on the progression of cerebral lesions -ES
Minoryx Therapeutics S.L.

FRAMES: A Double-Blind, Placebo-controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological and Clinical Markers in Patients With Friedreich's Ataxia - ES (completed)
Minoryx Therapeutics S.L.

An Open-label, Multicenter Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) -FR
Minoryx Therapeutics S.L.

NEXUS: An Open-label, Multicenter Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) -DE
Minoryx Therapeutics S.L.

ADVANCE: A randomized, double-blind, placebo-controlled, multinational, multicenter study with open-label treatment extension to assess the effect of MIN-102 on the progression of adrenomyeloneuropathy in male patients with X-linked adrenoleukodystrophy - FR
Minoryx Therapeutics S.L.